We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From May 2019 to May 2024
By Josh Beckerman
Voyager Therapeutics Inc. shares were recently down 11% to $10.06 following the gene therapy company's announcement Monday afternoon that its collaborations with AbbVie Inc. have ended.
"Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases," the company said. Voyager retains full rights to the vectorization technology and certain antibodies developed as part of the collaborations.
HC Wainwright & Co. cut its price target to $14 from $18 on Tuesday, maintaining its buy rating. Wedbush, which maintains an outperform rating, believes the "dissolution likely has more to do with strategic shifts at ABBV versus anything specific from the collaboration."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 04, 2020 13:11 ET (17:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
